Pandion Therapeutics Closes $80M in Series B Back to HomeCAMBRIDGE, MA, Pandion Therapeutics announced that it has closed an $80 million Series B financing led by Access Biotechnology and Boxer Capital.

Pandion Therapeutics, Inc., a clinical-stage, privately-held biotechnology company developing modular protein therapeutics for autoimmune disease, today announced that it has closed an $80 million Series B financing.

The financing round was led by Access Biotechnology and Boxer Capital and included other new investors RA Capital and OrbiMed.

About PT101PT101 is an interleukin 2 (IL-2) mutein Fc fusion protein therapy designed to potently and selectively expand regulatory T cells for the treatment of autoimmune disease.

About Pandion TherapeuticsPandion Therapeutics is developing modular biologics for autoimmune regulation that are designed to achieve lasting therapeutic outcomes for patients with autoimmune and inflammatory diseases. | To read full story, visit https://startuparound.com/read/1585753211.072374/Pandion-Therapeutics-Closes-$80M-in-Series-B?ref=audio_experience